May 17, 2020 07:25 AM IST
Mazumdar-Shaw said that the world is waiting for a vaccine for COVID-19 but till the time it is developed, there is a need to conduct tests and build a treatment regime to save lives.
- May 15, 2020 09:35 AM IST
- May 15, 2020 09:31 AM IST
Revenue from operations was up 3 percent at Rs 1,581 crore versus Rs 1,528.8 crore year-on-year.
- May 15, 2020 08:27 AM IST
Revenue was up 3 percent to Rs 1,581 crore versus Rs 1,529 crore.
- May 12, 2020 09:53 AM IST
The inspection was inspected by the regulatory agency between January 20 and 23, 2020.
- May 08, 2020 01:11 PM IST
The company has received the EIR from the US Food and Drug Administration (USFDA) for the pre-approval and good manufacturing practice inspection of its small molecules active pharmaceutical ingredient (API) manufacturing facility at Biocon Park SEZ, Bengaluru, it said in a filing to BSE.
- May 08, 2020 10:06 AM IST
The inspection was conducted between January 20 and January 24, 2020.
- Apr 18, 2020 08:45 PM IST
"The seismic events unleashed by the COVID-19 pandemic will have a powerful impact on the world we live in, changing it in ways we had never imagined were possible. The economic damage is likely to be unprecedented," Mazumdar-Shaw said.
- Apr 16, 2020 12:33 PM IST
LIC also raised its stake to 1.55 percent at the end of March quarter, from 1.16 percent in previous quarter. However FPIs cut their stake in the company to 14.98 percent during the quarter, from 16.09 percent QoQ.
- Apr 16, 2020 10:15 AM IST
The inspection was conducted between September 10 and September 19, 2019, a company spokesperson said, adding, Biocon Biologics has responded to the regulator on the eight observations from this inspection, in October last year.
- Apr 11, 2020 04:25 PM IST
The biopharmaceutical major, led by Kiran Mazumdar Shaw, has written to the West Bengal government offering medicines, including "additional support" services, to assist the state officials.
- Apr 09, 2020 12:28 PM IST
Mazumdar-Shaw said testing by private labs will plummet, since they are conducting the tests at an upfront cost.
- Apr 01, 2020 01:18 PM IST
COVID-19 crisis has shown us that we have to focus on these very important healthcare areas. Infectious diseases have been neglected and ignored for too long, Mazumdar-Shaw pointed out.
- Apr 01, 2020 10:30 AM IST
In a regulatory filing the company said, Biocon Sdn Bhd, a subsidiary of Biocon Ltd has received the EIR from the USFDA for the Pre-Approval Inspection (PAI) of its insulin manufacturing facility in Malaysia, for Insulin Glargine.
- Apr 01, 2020 09:50 AM IST
Company's subsidiary Biocon Sdn Bhd has received the establishment inspection report (EIR) from the US FDA for the pre-approval inspection of the Malaysia facility.
- Mar 27, 2020 04:23 PM IST
Biocon will continue to operate essential pharmaceutical manufacturing in full compliance with government requirements, it added.
- Mar 23, 2020 02:55 PM IST
Shaw said that COVID-19 is still under control in India, but we need to be very careful.
- Mar 20, 2020 09:30 AM IST
The inspection was conducted between February 20 to 26, 2020 and EIR has been closed with a “VAI” classification.
- Feb 27, 2020 09:46 AM IST
The USFDA conducted a post-approval and GMP inspection of the small-molecule API manufacturing facility in the Biocon Campus in Bengaluru between February 20 and 26.
- Feb 25, 2020 11:54 AM IST
The USFDA had issued a Form 483 with five observations for Bengaluru unit.
- Feb 20, 2020 04:49 PM IST
When asked about the situation with regards to supply and raw material prices, Mazumdar Shaw said, "If this continues beyond six months, we do have to worry about the impact. For now, we are okay."
- Feb 19, 2020 09:40 PM IST
Reiterating on the importance of primary healthcare, she said, "It is the starting point for looking at how to basically diagnose early, how to basically create awareness, how to basically immunise people in a community."
- Jan 28, 2020 12:15 PM IST
- Jan 28, 2020 12:08 PM IST
- Jan 27, 2020 09:23 PM IST
The biologics segment grew 50 percent year-on-year (YoY) in nine-month period to Rs 1594 crores, led primarily by contributions from Pegfilgrastim and Trastuzumab in US market.